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Abstract
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There is a need to develop a colorectal cancer (CRC) screening test that is noninvasive, cost
effective, and sensitive enough to detect preneoplastic lesions. This case-control study examined
the feasibility of using circulating extracellular miRNAs to differentiate a spectrum of colorectal
neoplasia of various severity and hence for early detection of colorectal neoplasia.
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Archived serum samples of 10 normal controls and 31 cases, including 10 with non-advanced
adenoma, 10 with advanced adenoma, and 11 with CRC, were profiled for circulating miRNAs
using next-generation sequencing. Multiple linear regression, adjusting for age, gender, and
smoking status, compared controls and the three case groups for levels of 175 miRNAs that met
stringent criteria for miRNA sequencing analysis. Of the 175 miRNAs, 106 miRNAs were downregulated according to severity of neoplasia and showed a relative decrease in expression from
controls to non-advanced adenoma to advanced adenoma to CRC (Ptrend < 0.05). Pair-wise group
comparisons showed that 39 and 80 miRNAs were differentially expressed in the advanced
adenoma and CRC groups, as compared to the controls, respectively. Differences in miRNA levels
between the non-advanced adenoma group and controls were modest.

Reprint requests: Gloria Y.F. Ho, PhD., Department of Epidemiology & Population Health, Albert Einstein College of Medicine, 1300
Morris Park Avenue, Belfer 1312, Bronx, NY 10461 (Phone: 718 430 3558; Fax: 718 430 3076; gloria.ho@einstein.yu.edu)..
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
None of the authors have any financial or personal relationship with organizations that could potentially be perceived as influencing
the described research, and all authors have read the journal's policy on disclosure of potential conflicts of interest. All authors have
read the journal's authorship agreement and that the manuscript has been reviewed by and approved by all named authors.

Ho et al.

Page 2

Author Manuscript

Our study found that expression of many miRNAs in serum was inversely correlated with the
severity of colorectal neoplasia, and differential miRNA profiles were apparent in preneoplastic
cases with advanced lesions, suggesting circulating miRNAs could serve as potential biomarkers
for CRC screening.

INTRODUCTION

Author Manuscript

Screening for colorectal cancer (CRC) by fecal occult blood test (FOBT), fecal
immunochemical test (FIT), flexible sigmoidoscopy (FSG), and colonoscopy can lower the
incidence and mortality of colorectal cancer.1-5 However, these recommended screening
methods have shortcomings; FOBT and FIT have a low sensitivity (~40%) for detecting
preneoplastic lesions,4,5 while FSG and colonoscopy are limited by their high costs, the
requirement of bowel preparation, and their invasive nature.5,6 Therefore, compliance
remains an issue for CRC screening. In 2012, only 65% of adults aged 50-75 years were upto-date with the U.S. Preventive Services Task Force recommendations for CRC screening.7
There is a pressing need to develop a screening test that is sensitive, noninvasive, and cost
effective to detect biomarkers for both CRC and advanced preneoplastic lesions.
MiRNAs, small non-coding RNAs of ~22 nucleotides in length, mediate gene silencing by
binding to specific mRNA targets and repressing translation of mRNA through degradation
and/or translational inhibition.8,9 As such, they have profound effects on regulating gene
expression, including genes that are involved in tumorigenesis.10 Extracellular miRNAs
have the potential to serve as cancer biomarkers because they are derived from cells, show
tissue specific expression,11,12 and present in peripheral blood in a remarkably stable
form.13-15 In addition, tumors can be a source of circulating miRNAs.13,16-18

Author Manuscript

Because of these properties, a noninvasive blood test for assessment of extracellular miRNA
markers in circulation could potentially be useful as a screening test for CRC. This is
supported by observations that differential miRNA expression profiles were found between
colorectal tumor and normal tissues,19-22 that miRNAs dysregulated in tumor tissues also
had aberrant levels in plasma of the same colorectal cancer patients,22,23 and that circulating
levels of specific miRNAs decreased after tumor resection.22,23 Epidemiological studies
have also shown differential circulating miRNA profiles between normal controls and
individuals with either advanced adenoma or CRC.22-33

Author Manuscript

However, none of the previous epidemiological studies have examined whether circulating
miRNA concentrations vary across the spectrum of neoplasia (i.e., from normal to nonadvanced adenoma to advanced adenoma to CRC). If so, a screening test for miRNA
markers may be feasible for prevention and early detection of CRC. This is the first casecontrol study of colorectal neoplasia to comprehensively profile circulating miRNAs in
serum using next-generation sequencing and to correlate miRNA levels with severity of
colorectal neoplasia.
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MATERIAL AND METHODS
Study population

Author Manuscript

Thirty-one cases with various degree of colorectal neoplasia and 10 controls were identified
from the Digestive Diseases Tissue Resource at the University of Pittsburgh. This program
routinely collects and archives tissue and blood samples from individuals who participated
in colonoscopy screening as well as from those who were diagnosed with CRC in doctors'
offices. With informed consent, blood samples were collected before colonoscopy from
screening participants or before treatment for colorectal cancer cases, processed within 1-2
hours of collection, and serum samples were stored at -80°C. The 31 cases in this study
included 10 with non-advanced adenoma, 10 with advanced adenoma, and 11 colorectal
cancer patients. Of the cancer patients, all had adenocarcinoma, 5 had stage I/II cancer, and
6 had stage III/IV cancer. The 10 controls were individuals who were screen negative by
colonoscopy.
In addition to the 41 samples from cases and controls, duplicate aliquots from the same
blood sample from six subjects were included to assess reproducibility of miRNA
sequencing. All 47 samples were processed blindly without knowledge of the case-control
status or identity of the duplicate samples. The study protocol was approved by the
institutional review board of the two institutes involved in this study; it was carried out
according to The Code of Ethics of the World Medical Association (Declaration of
Helsinki), and informed consent was obtained.
Lab procedures

Author Manuscript

Total RNA was purified from 300 μL of serum using the miRNeasy serum/plasma kit
(Qiagen). The median total RNA yield was 32 ng/10 L (range:15 - 61). From this, 10 ng of
total RNA was used for small RNA cDNA library preparation. Quality of the library
constructs was examined using High Sensitivity DNA Chip Kit (Agilent Technologies) for
number of peaks, size distribution, and concentration of fragments. All samples showed a
library peak around 145 bp, which corresponds to the 5’-3’ adapter ligated miRNA
constructs derived from the 20-30 nucleotides small RNAs.

Author Manuscript

MiRNA sequencing was done by Illumina Hi-Seq2000. To analyze sequencing data, we
developed an automated analytical pipeline. Briefly, data provided from the HiSeq2000
sequencer in a standard fastq format were trimmed of adapter sequences and low quality
reads (more than 3 low quality base-calls) through a C++ program.34 These sequences were
then collapsed to remove redundancy using the Galaxy Genome Browser tool fastx,35
followed by alignment to the known human miRNA/small RNA database, miRBase (http://
www.mirbase.org/), release 19 (August 2012).36 Before statistical analysis, miRNA read
counts were normalized using the reads per million (rpm) method, which divided read count
of a given miRNA by the total number of miRNA reads in that sample and multiplied by a
million.37 Following normalization, we applied stringent criteria for a miRNA to be
considered for statistical analysis, namely to be present in at least 50% of study samples in
greater than 10 copy numbers. MiRNAs with less than 10 reads were not included due to the
error rate of Illumina sequencing and stochastic variation in gene expression.38 Of the 822
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unique miRNAs that were detected, 175 were retained for data analysis. The top two
miRNAs that showed differential expression between cases and controls were verified by
qRT-PCR.
Statistical analysis
We first assessed reproducibility of miRNA sequencing. Six individuals were sequenced
twice. For each person, we calculated Spearman rank correlation coefficient between the
duplicate values of 175 miRNAs. For these six subjects, one of the duplicate samples was
randomly selected for further statistical analysis described below.

Author Manuscript

The effects of serum storage on miRNA sequencing were evaluated by Spearman rank
correlations between serum storage duration (months between blood draw and RNA
extraction) and total miRNA reads in 41 samples. In addition, for each of the175 miRNAs,
we examined the Spearman rank correlation between its read count and serum storage time.

Author Manuscript

The four study groups (colorectal cancer, advanced adenoma, non-advanced adenoma, and
controls) were first examined for differences in the established risk factors for colorectal
neoplasia, namely age, gender, race/ethnicity, smoking status, and body mass index (BMI),
by Mantel-Haenszel chi-square test for trend for categorical variables and by Kruskal-Wallis
test for continuous variables. We then compared values of each miRNA among the four
study groups using multiple linear regression adjusting for covariates significantly
associated with colorectal neoplasia in this study population, including age, gender, and ever
smoking. The outcome variable was the log2 transformed normalized miRNA read counts.
The regression model generated three β coefficients; each represented the difference in mean
miRNA values between a case group and the controls. As read counts were log2
transformed, the β coefficient was equivalent to the log ratio of geometric mean miRNA
values of a case group versus that of the control group (i.e., log2 of fold-change). P values
for global tests (evaluating significance of all 3 βs simultaneously) and 2-group comparisons
(evaluating significance of each β) were obtained.
P values for trend tests were generated by coding and analyzing the four study groups in one
linear variable. P values were adjusted for multiple comparisons. An arbitrary cutoff of 0.05
for false discovery rate (FDR) according to the Benjamini and Hochberg procedure was
applied to determine statistical significance.39

RESULTS
Reproducibility of miRNA sequencing

Author Manuscript

Duplicate aliquots of the same serum sample from six subjects were processed and
sequenced twice to assess reproducibility of miRNA sequencing. The correlations between
duplicate values of 175 miRNAs in these six individuals ranged from 0.93 to 0.99 (median =
0.97), indicating excellent reproducibility of miRNA sequencing. Figure 1 shows the
duplicate miRNA read counts of one subject.
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Median storage duration of the 41 serum samples was 29.4 months (range 11.1 – 90.2).
There was little correlation between serum storage duration and total miRNA reads from
sequencing (r = -0.06). Of the175 miRNAs, 166 (95%) of them had a weak to modest
correlation (≤ 0.3) between their read counts and storage duration.
Differential miRNA expression according to severity of neoplasia
Median age of the 41 subjects was 61 years old (range 28 - 91), 49% were males, and 95%
were Caucasians; 22 (54%) subjects ever smoked cigarettes, but only 4 (10%) were current
smokers. Cases, particularly those with advanced adenoma or CRC, tended to be older and
were more likely to be a male and an ever-smoker than controls (Table 1).

Author Manuscript

The geometric mean counts of 175 miRNAs in the cases and controls, their fold changes
adjusted for age, gender, and smoking status, and FDR adjusted p values are shown in
Supplemental Table 1. Heatmap in Figure 2 shows differential expression of miRNAs in the
four study groups. Levels of 109 miRNAs were significantly correlated with the severity of
colorectal neoplasia, as indicated by their p values for trend test (Supplemental Table 1). Of
these, levels of 106 miRNAs were inversely associated with the extent of neoplasia and
showed a relative decrease in miRNA levels from the controls to non-advanced adenoma to
advanced adenoma to the CRC groups. As an example, Figure 3A shows boxplot of
miRNA-30b (Ptrend = 1.9×10−6), which was the most significant among the 106 miRNAs
that were down-regulated in the cases. Three miRNAs were up-regulated in the cases with
levels increasing with the severity of neoplasia (miRNA-486, miRNA-25, and
miRNA-1180). Boxplot of miRNA-486 (Ptrend = 4.1×10−4), the most significant of the three,
is shown in Figure 3B.
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Differential miRNA expression in pair-wise group comparisons

Author Manuscript

Two-group comparisons showed that the smallest differences in miRNA levels were
between the non-advanced adenoma group and controls, and none of the miRNAs were
significantly different between groups. On the other hand, 39 miRNAs were differentially
expressed between the advanced adenoma and control groups, and 80 miRNAs were
differentially expressed between the CRC and control groups (Supplemental Table 1). As
examples, Table 2 shows the top 2 miRNAs (miRNA-30b and miRNA-30c) that were the
most significantly different between the CRC and control groups and the top 2 miRNAs
(miRNA-146a and miRNA-30d) that were differentially expressed in the advanced adenoma
group. Expression levels of miRNA-30b and miRNA-146a were verified by qRT-PCR. The
Spearman rank correlations between qRT-PCR and Illumina sequencing expression levels
were 0.61 for miRNA-30b and 0.79 for miRNA-146a; qRT-PCR expression patterns in the
study groups were consistent with the Illumina sequencing data (Supplemental Figure 1).
We also repeated the analyses excluding 6 CRC cases with advanced stage III/IV disease to
explore if serum miRNAs had the potential to detect early cancers. The results were similar
(data not shown). For example, miRNA-30b and miRNA-30c were still among the top
miRNAs with significant differential levels between stage I/II CRC cases and controls (FDR
adjusted p values were .004 and .007, respectively).
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DISCUSSION
In this case-control study of colorectal neoplasia, we examined the feasibility of sequencing
circulating extracellular miRNAs in archived serum samples and demonstrated that nextgeneration sequencing of miRNA had excellent reproducibility, and that archived serum
samples were suitable for this technology. Serum storage duration did not affect quantity of
total miRNA or levels of individual miRNAs in serum. Previous studies have also found
circulating miRNAs to be present in a remarkably stable form that is resilient to freezethawing (as many as 10 cycles), RNase degradation, extended storage, and extreme
temperature and pH.13-15 These observations suggest that archived serum samples from
existing cohort and case-control studies could provide valuable resources for efficient
evaluation of circulating miRNAs as cancer biomarkers.

Author Manuscript

We also assessed the feasibility of using miRNAs, profiled by sequencing, to distinguish
normal controls from cases with various degree of colorectal neoplasia. We found levels of
many miRNAs to be inversely correlated with the extent of neoplasia. About 12 case-control
studies in the literature compared circulating miRNAs between normal controls and cases
with either CRC or advanced adenoma.22-33 Most studies found up-regulation of miRNAs in
cases, although specific miRNAs were rarely replicated except for miRNA-21 22,31,33 and
miRNA-29a 25,29,31 that were found to be over-expressed in CRC cases in three studies. Our
results suggesting that serum concentrations of many miRNAs, including miRNA-21 and
miRNA-29a, were down-regulated in the cases were inconsistent with those from previous
studies. Nevertheless, down-regulation of miRNA expression globally in tumors as
compared to normal tissues had been reported previously.12
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This discrepancy could be due to the differences in the miRNA detection platform and type
of blood sample. While other studies of colorectal neoplasia used qRT-PCR for a few
specific miRNAs or microarrays, our study was the first to use miRNA next-generation
sequencing. Moreover, almost all previous studies used plasma samples, but we used serum.
It has been shown that for some miRNAs, their levels in plasma are different from those in
serum.40,41 MiRNA levels in plasma can be affected by centrifugation conditions, hence the
amount of residual platelets and cellular debris that contribute miRNAs, and also by certain
anticoagulants (e.g., citrate or heparin) that inhibit qRT-PCR.9,40,42,43 Nevertheless, our
results were unlikely to be attributed to systematic biases. This is because, in our study,
miRNAs were not only down-regulated in cases but also decreased with the severity of
colorectal neoplasia in a linear trend; blood samples of the adenoma cases and controls were
collected before colonoscopy when neoplastic outcome was not known, and all serum
samples were processed and sequenced without knowledge of the case-control status.

Author Manuscript

Our finding that many miRNAs had significantly lower circulating levels in the cases than
controls raises a practical concern of whether down-regulated miRNAs could be utilized as
cancer biomarkers in a clinical setting, if their low levels are difficult to be detected by qRTPCR, a technology that is commonly available in clinical diagnostic laboratories, but less
sensitive than next-generation sequencing. In our study, the top 2 miRNAs, namely
miRNA-30b and miRNA-146a, that were down-regulated in CRC and advanced adenoma
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cases, respectively, were verified by qRT-PCR, demonstrating in principle that qRT-PCR
could amplify and detect cancer biomarkers that circulate in a below normal level.
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In this study, several members in the miRNA-30 family (miRNA-30b, -30c, and -30d) were
among the top miRNAs down-regulated in cases with either advanced adenoma or CRC. It
is intriguing that low expression of the miRNA-30 family members have been reported in
breast, lung, and colorectal cancers.44-48 MiRNA-30b, the top miRNA down-regulated in
CRC cases in our study, may function as a tumor suppressor – it had lower expression in
CRC tissue than normal tissues, suppressed growth of CRC cell lines, and repressed
expression of KRAS, PIK3CD, and BCL2 genes.47 MiRNA-30d was one of the top miRNAs
down-regulated in cases with advanced adenoma in our study. MiRNA-30d targets GRP78,
a protein that is commonly over-expressed in cancers as a major endoplasmic reticulum
chaperone and signaling regulator, and has also been found to be down-regulated in colon
tumors and a colon cancer cell line.48
MiRNA-146a was another top miRNA that was significantly down-regulated in cases with
advanced adenoma. It is involved in innate immunity by inhibiting Toll-like receptor
signaling and regulating cytokine responses. MiRNA-146a may function as a key negative
regulator of inflammation 49-51 and could be involved in the pathogenesis of colorectal
neoplasia, an inflammation-associated disease.52-54 Of the miRNAs that were up-regulated
among cases with advanced adenoma or CRC, MiRNA-486 was the most significant. Its role
in carcinogenesis, however, is not quite clear. It was reported to suppress NF-κB-negative
regulators, resulting in sustained NF-κB activity, in one study,55 but shown to inhibit tumor
growth in others.56,57 Nevertheless, one study found up-regulation of miRNA-486 in
colorectal cancer tissue to be associated with KRAS mutation.58

Author Manuscript
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With a small sample size, this study was not designed to identify and validate diagnostic or
early detection miRNA markers for colorectal neoplasia, but rather a proof of concept to
demonstrate differential expression of circulating miRNAs according to severity of disease
using next-generation sequencing, which, to the best of our knowledge, has not been studied
previously. To further pursue the potential of measuring circulating miRNAs for CRC
screening, future studies need to focus on several areas that are neglected by existing studies
so far: (1) to discover differentially expressed circulating miRNA markers in cases targeted
by screening, specifically a large sample size of individuals with early stage I-II CRC or
advanced adenoma; (2) to identify and validate promising miRNA markers while adjusting
for possible confounding factors, such as presence of inflammatory bowel disease or other
inflammatory conditions, that could affect miRNA expression in study groups; (3) to
evaluate whether serum levels of promising markers correlate with those in tissue and are
specific for colorectal neoplasia; (4) to examine variation and latency of these promising
miRNAs over time in serial blood samples; and (5) to assess the intended clinical utility of
qRT-PCR in detecting promising miRNA markers in a target population for CRC screening.
Given that most significant markers were down-regulated in individuals with disease in our
study, it would be crucial for future studies to pinpoint the markers that, despite their levels
in diseased individuals are below normal, can be detected reliably with high sensitivity by a
clinical diagnostic technology.
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In summary, in this study of circulating miRNAs in colorectal neoplasia, we found that
levels of circulating miRNAs correlated with severity of colorectal neoplasia. Moreover,
cases with neoplastic lesions, as early as advanced adenoma and stage I/II CRC, had
differential miRNA profiles compared to normal controls. These results, if confirmed and
validated, suggest that miRNAs have the potential to be screening biomarkers for prevention
and early detection of CRC.
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BMI

body mass index
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colorectal cancer

FDR

false discovery rate
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fecal immunochemical test
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fecal occult blood test
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flexible sigmoidoscopy

miRNA

micro-RNA

RT

reverse transcription
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Translational Significance
Our study found that levels of circulating miRNAs, determined by sequencing, correlated
with severity of colorectal neoplasia. Cases with neoplastic lesions, as early as advanced
adenoma and stage I/II cancer, had differential miRNA profiles compared to controls,
suggesting that miRNAs have the potential to be screening biomarkers for prevention and
early detection of colorectal cancer.
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Figure 1.

Replicate read counts of 175 miRNAs in one sample
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Figure 2.
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Heatmap of expression of 175 miRNAs (rows) in 41 serum samples (columns) Red=High
relative expression. Green= Low relative expression
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Figure 3.

Boxplots of miRNA-30b (A) and miRNA-486 (B) read counts in the study groups
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*

Ever smoked, n (%)

Male, n (%)

Median BMI (IQR)

54.5 (52-65)

3 (30)

4 (40)

30.7 (25.8-31.2)

IQR = Inter-quartile range.

*

*

Median age (IQR)

Controls (n=10)

3 (30)

2 (20)

29.3 (26.6 – 34.3)

59.5 (57-72)

Non-advanced adenoma (n=10)

8 (80)

6 (60)

31.0 (23.8 – 36.5)

57.5 (54 – 79)

Advanced adenoma (n=10)

8 (73)

8 (73)

31.5 (27.0 – 37.1)

68.0 (61 – 87)

Colorectal cancer (n=11)
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Characteristics of cases with colorectal neoplasia and controls

0.012

0.047

0.851

0.093

P value
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30130

30d

12646

519

1074

616

Advanced adenoma

13104

973

540

288

CRC

0.41

0.09

0.30

0.34

Advanced adenoma vs controls

Fold change

0.39

0.13

0.14

0.17

CRC vs controls

MiRNA-146a and miRNA-30d had the lowest FDR adjusted p values when the advanced adenoma group was compared to the controls.

†

3.1 × 10−3

1.7 × 10−2

†

*

*

4.9 × 10−3

1.9 × 10−3

0.4 × 10−3

†

0.7 × 10−3

0.034

0.028

CRC vs controls

FDR adjusted P value
Advanced adenoma vs controls

MiRNA-30b and miRNA-30c had the lowest FDR adjusted p values when the CRC group was compared to the controls.

*

6442

4241

30c

146a

2309

Controls

30b

miRNA

Geometric mean count

The top miRNAs differentially expressed in cases with advanced adenoma or CRC compared to controls
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